Coeptis Therapeutics, Inc. (COEP) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 113.77K | 862.05K | 237.44K | 200.68K | 62.87K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 80.95% | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 45.16K | 45.16K | 45.16K | 45.16K | 45.16K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 39.69% | 5.24% | 19.02% | 22.5% | 71.82% | - | - | - | - | - | - | - |
| Gross Profit | 68.61K | 816.89K | 192.29K | 155.52K | 17.72K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | 60.31% | 94.76% | 80.98% | 77.5% | 28.18% | - | - | - | - | - | - | - |
| Gross Profit Growth % | 287.26% | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 3.98M | 2.81M | 2.67M | 4.68M | 4.07M | 2.16M | 2.14M | 2.83M | 2.92M | 3.54M | 7.9M | 3.68M |
| OpEx % of Revenue | 3501.12% | 325.41% | 1124.2% | 2330.43% | 6480.74% | - | - | - | - | - | - | - |
| Selling, General & Admin | 644.7K | 2.24M | 1.83M | 4.14M | 3.74M | 1.57M | 1.08M | 2.18M | 1.9M | 2.35M | 2.58M | 2.97M |
| SG&A % of Revenue | 566.67% | 260.11% | 771.57% | 2061.2% | 5945.29% | - | - | - | - | - | - | - |
| Research & Development | 235.53K | 312.9K | 587.28K | 290.31K | 86.66K | 343.88K | 811.78K | 398.82K | 777.07K | 1.28M | 5.07M | 466.63K |
| R&D % of Revenue | 207.02% | 36.3% | 247.34% | 144.66% | 137.83% | - | - | - | - | - | - | - |
| Other Operating Expenses | 1000K | 250K | 250K | 250K | 250K | 250K | 250K | 250K | 250K | -93.85K | 250K | 250K |
| Operating Income | -3.91M | -1.99M | -2.48M | -4.52M | -4.06M | -2.16M | -2.14M | -2.83M | -2.92M | -3.54M | -7.9M | -3.68M |
| Operating Margin % | -3440.81% | -230.64% | -1043.22% | -2252.94% | -6452.56% | - | - | - | - | - | - | - |
| Operating Income Growth % | 3.51% | 8.04% | -15.65% | -59.87% | -38.82% | 38.94% | 72.89% | 23.25% | 55.31% | -16.35% | -41.89% | 62.45% |
| EBITDA | -3.66M | -1.68M | -2.17M | -4.22M | -3.75M | -1.9M | -1.86M | -2.58M | -2.66M | -3.29M | -7.62M | -3.43M |
| EBITDA Margin % | -3221.07% | -195.15% | -914.44% | -2100.69% | -5966.99% | - | - | - | - | - | - | - |
| EBITDA Growth % | 2.32% | 11.56% | -16.51% | -63.52% | -40.88% | 42.19% | 75.55% | 24.94% | 57.65% | -17.82% | -43.29% | 64.08% |
| D&A (Non-Cash Add-back) | 250K | 306.01K | 305.76K | 305.53K | 305.3K | 259.98K | 278.23K | 250K | 259.34K | 250.31K | 280.55K | 250.31K |
| EBIT | -3.76M | -1.18M | -2.84M | -4.27M | -3.35M | -2.93M | -1.78M | -2.97M | -2.8M | -4.01M | -6.33M | -3.16M |
| Net Interest Income | -5.26K | -324K | -62.61K | -67.79K | -71.49K | -78.63K | -50.93K | -66.06K | -200.5K | -13.83K | -19.8K | -42.64K |
| Interest Income | 0 | 116.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 5.26K | 440.49K | 62.61K | 67.79K | 71.49K | 78.63K | 50.93K | 66.06K | 200.5K | 13.83K | 19.8K | 42.64K |
| Other Income/Expense | -106.25K | 365.37K | -421.74K | 186.63K | 636.04K | -849.55K | 312.88K | -207.24K | -79K | -483.47K | 1.55M | 482.36K |
| Pretax Income | -4.02M | -1.62M | -2.9M | -4.33M | -3.42M | -3.01M | -1.83M | -3.04M | -3M | -4.02M | -6.35M | -3.2M |
| Pretax Margin % | -3534.2% | -188.26% | -1220.84% | -2159.94% | -5440.95% | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.02M | -1.58M | -2.74M | -3.53M | -3.06M | -1.95M | -1.73M | -3.04M | -3M | -4.02M | -6.35M | -3.2M |
| Net Margin % | -3534.2% | -183.04% | -1153.72% | -1761.3% | -4863.27% | - | - | - | - | - | - | - |
| Net Income Growth % | -31.5% | 19% | -58.11% | -16.45% | -1.88% | 51.6% | 72.72% | 5.22% | 62.28% | -36.74% | -12.42% | 67.33% |
| Net Income (Continuing) | -4.02M | -1.62M | -2.9M | -4.33M | -3.42M | -3.01M | -1.83M | -3.04M | -3M | -4.02M | -6.35M | -3.2M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 401.88K | 506.16K | 551.2K | 984.3K | 984.3K | 682.06K | 157.68K | 132.49K | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.65 | -0.29 | -0.58 | -0.95 | -0.99 | 4.09 | -0.05 | -0.08 | -0.08 | -0.11 | -0.23 | -0.14 |
| EPS Growth % | 34.34% | -107.09% | -1163.62% | -1075.74% | -1072.99% | 3818.18% | 80.04% | 42.29% | 81.65% | 45% | 17.86% | 70.83% |
| EPS (Basic) | -0.65 | -0.29 | -0.58 | -0.95 | -0.99 | 4.09 | -0.05 | -0.08 | -0.08 | -0.11 | -0.23 | -0.14 |
| Diluted Shares Outstanding | 6.03M | 4.23M | 4.75M | 3.71M | 3.07M | 1.92M | 39.81M | 37.57M | 35.54M | 35.33M | 26.65M | 21.81M |
| Basic Shares Outstanding | 6.03M | 4.23M | 4.75M | 3.71M | 3.07M | 1.92M | 39.81M | 37.57M | 35.54M | 35.33M | 26.65M | 21.81M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |